Novavax, Inc. (NASDAQ: NVAX) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning, and for good reason. The company announced preclinical data with regard to a vaccine candidate, leading to excitement among investors and sending the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:05), NVAX is trading at $1.07 per share after a gain of $0.07 per share or 7.00% thus far today.
NVAX Gains On Preclinical Data
As mentioned above, Novavax is having a strong start to the day in the pre-market hours after announcing preclinical data surrounding an influenza vaccine candidate. The data came from a preclinical study and has been published in the journal Vaccine. The goal of the vaccine is to protect older adults from seasonal influenza.
The study the data came from was conducted in ferrets. NVAX said that the study found that NanoFlu induced hemagglutination-inhibition and microneutralizing antibodies against a broad range of influenza subtypes. In the study, NanoFlu was shown to elicit higher HAI and MN antibody responses exceeding those induced by the high-dose vaccine against recent (homologous) A(H3N2) by 7-fold, A(H1N1) by 26-fold, and B strain viruses by 2-fold. In a statement, Stanley C. Erck, President and CEO at NVAX, had the following to offer with regard to the data…
“Novavax has over a decade of experience in developing both seasonal and pandemic influenza vaccine candidates. Based on the superior attributes of our nanoparticle based vaccine candidates, we transitioned our influenza development activities to our nanoparticle vaccine platform… The data in this publication further validate our nanoparticle vaccine platform and provide a strong rationale for advancing NanoFlu into a Phase 1/2 clinical trial. Our goal is to deliver a superior, differentiated vaccine to the greater than $3 billion global seasonal influenza commercial market.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the company’s ongoing work, not only with regard to NanoFlu, but other vaccines across their robust pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!